This activity is supported by an educational grant from Pfizer.
"Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers" is a live continuing medical education (CME)-certified symposium to be held adjunct to the 33rd Annual Miami Breast Cancer Conference®.
Treatment of estrogen receptor–positive (ER+), human epidermal growth factor 2–negative (HER2-), metastatic breast cancer remains an area of significant unmet clinical need. Efforts to improve upon the outcomes achieved with initial endocrine therapy have been largely unsuccessful, but active research into this area is expanding the arsenal of targeted therapies available for metastatic breast cancer. While novel therapies and combinations—such as a recently FDA-approved oral, highly selective CDK4/6 inhibitor—undeniably benefit patients with breast cancer, they also add markedly to the complexity of the treatment decision-making process. With the potential for broader indications of CDK4/6 inhibitory therapy in breast and other tumor types, these agents are likely to become more routinely used.
For this not-to-be-missed symposium, we are bringing together a panel of internationally recognized experts in breast cancer therapy to discuss how CDK4/6 inhibitors can advance the care of these patients, today and in the future. Faculty will cover key topics in the treatment of ER+, HER2-, metastatic breast cancer including:
The symposium will be held at the Fontainebleau Miami Beach on March 12 from 7:00 am–8:30 am. Please join us live in Miami to learn the latest and greatest state-of-the-art science around CDK4/6 inhibitory therapies in ER+, HER-, metastatic breast cancer, as well as the most up-to-date information on appropriate and optimal use of these agents.
This will be the only independent CME-certified symposium focused entirely on CDK4/6 inhibitory therapy for metastatic breast cancer. You won’t want to miss this program!
This activity is intended for all attendees of the Miami Breast Cancer Conference® including medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.
After successful completion of this educational activity, participants should be able to:
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Joyce O'Shaughnessy, MD
Chair, Breast Cancer Research
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY